For the current week, the overall ratings of six Pharmaceutical stocks are worse, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
AstraZeneca (NYSE:AZN) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. Astrazeneca is a biopharmaceutical company focused on therapy related to cardiovascular health, gastrointestinal health, infection, neuroscience, oncology and respiratory health, and inflammation. For Portfolio Grader’s specific subcategory of Sales Growth, AZN also gets an F. Shares of the company have declined 0.9% from a month prior. For more information, get Portfolio Grader’s complete analysis of AZN stock.
This week, Depomed‘s (NASDAQ:DEPO) rating worsens to a D from the company’s C rating a week ago. Depomed is a specialty pharmaceutical company focused on the development and commercialization of differentiated products that address large and growing markets and are based on proprietary oral drug delivery technologies. The stock gets F’s in Earnings Momentum, Equity, and Cash Flow. Margin Growth and Sales Growth also get F’s. Over the last month, the price of DEPO has declined 7.8%, worse than the Nasdaq’s 6.9% drop for the same period. To get an in-depth look at DEPO, get Portfolio Grader’s complete analysis of DEPO stock.
Avanir Pharmaceutical‘s (NASDAQ:AVNR) rating weakens this week, dropping to a D versus last week’s C. Avanir Pharmaceuticals engages in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. The stock gets F’s in Equity and Cash Flow. The stock price has fallen 12.9% over the past month. As of Nov. 9, 2012, 14.9% of outstanding Avanir Pharmaceutical shares were held short. For a full analysis of AVNR stock, visit Portfolio Grader.
GlaxoSmithKline (NYSE:GSK) gets weaker ratings this week as last week’s C drops to a D. GlaxoSmithKline is a research-based pharmaceutical company. Over the past month, shares of GSK have dropped 5.4%. For more information, get Portfolio Grader’s complete analysis of GSK stock.
Pain Therapeutics (NASDAQ:PTIE) experiences a ratings drop this week, going from last week’s C to a D. Pain Therapeutics develops safer or more efficacious drugs for use in pain management, particularly in the area of opioid painkillers. The stock also gets an F in Equity. The stock price has fallen 45.7% over the past month. To get an in-depth look at PTIE, get Portfolio Grader’s complete analysis of PTIE stock.
Slipping from a C to a D rating, Ampio Pharmaceuticals (NASDAQ:AMPE) takes a hit this week. Ampio Pharmaceuticals engages in the discovery and development of pharmaceutical drugs and diagnostic products to identify, treat, and prevent metabolic disorders, eye diseases, kidney diseases, acute and chronic inflammation diseases, and male sexual dysfunction. The stock gets F’s in Equity and Cash Flow. AMPE’s stock price has fallen 4.9% from a month ago. For a full analysis of AMPE stock, visit Portfolio Grader.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
